Greg Verdine

Founder, Chief Executive Officer, and Board Member
LifeMine Therapeutics

Gregory Verdine is a pioneering scientist, educator, investor, and entrepreneur widely regarded as a founder of the field of chemical biology and one of the world’s leading innovators in new drug discovery. He is Founder, President, and CEO of LifeMine Therapeutics, Executive Chairman of VidaVinci, Erving Professor of Chemistry and Harvard College Professor, Emeritus, at Harvard University and Harvard Medical School, Managing General Partner of LoLa Capital, and a Venture Partner at Andreessen Horowitz.

Over a distinguished career spanning more than three decades, Dr. Verdine has cofounded more than a dozen biotechnology companies—including Parabalis Medicines (formerly FogPharma), WaVe Life Sciences, Warp Drive Bio, Enanta Pharmaceuticals, Eleven Biotherapeutics, Variagenics, Tokai Pharmaceuticals, Aileron Therapeutics, and Gloucester Pharmaceuticals, acquired by Celgene—which collectively have brought multiple FDA-approved medicines to patients and advanced numerous new drug modalities into clinical development. He is credited with coining the phrase “drugging the undruggable” to describe his life’s mission: transforming previously intractable disease targets into treatable ones through bold scientific innovation.

Dr. Verdine earned his Ph.D. in chemistry from Columbia University, his B.S. in chemistry from St. Joseph’s University, and trained as an NIH postdoctoral fellow at MIT and Harvard Medical School. He is a Fellow of the Royal Society of Chemistry and the American Association for the Advancement of Science, and has received numerous awards and honorary degrees recognizing his groundbreaking contributions to science and medicine.